NCT00712881 2024-02-23Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast CancerTeva Branded Pharmaceutical Products R&D, Inc.Phase 2 Completed126 enrolled 16 charts